Navigation Links
Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR

eleased inside of target cells. (Abstracts #658 and #4086)

In addition, data were reported on preclinical studies of ADCs targeted to glypican-3, CD133/prominin-1 and Lewis-Y, which are expressed in a variety of carcinomas including melanoma, ovarian, brain, colorectal and pancreatic cancers. Data were presented in multiple poster sessions demonstrating that ADCs to these targets are active and thus have therapeutic potential in the treatment of multiple types of solid tumors. (Abstracts #656, #1332 and #3332)

Several of Seattle Genetics' collaborators presented additional preclinical data on programs utilizing the company's ADC technology. These included presentations by Progenics, Genentech, MedImmune and Celera, an Applera Corporation business. (Abstracts #4102, #1551, #4468, #5744 and #1324)

SGN-33 and SGN-30 Programs

Data presented during AACR also illustrate ongoing preclinical activities with SGN-33 and SGN-30 to further define their therapeutic potential.

SGN-33 is a humanized monoclonal antibody currently in a single-agent phase I clinical trial for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In preclinical studies, SGN-33 reduces the tumor-induced activity of macrophages, suggesting a novel mechanism that may contribute to its antitumor activity. Seattle Genetics plans to advance SGN-33 into combination clinical trials during 2007, including a phase I study in combination with Revlimid(R) for MDS and a phase II study in combination with low-dose chemotherapy for AML. (Abstract #4111)

SGN-30 is currently in three phase II clinical trials in combination with chemotherapy for the treatment of Hodgkin's disease and anaplastic large cell lymphoma (ALCL) that are sponsored by the National Cancer Institute. Preclinical findings presented by the company during AACR further characterize SGN-30's mechanism of action. (Abstract #661)

Downloadable copies of Seattle Genetics' posters are available f
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
6. Myriad Genetics Presents Tumor Origin Technology at AACR
7. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
8. Myriad Genetics Presents Azixas Mode of Action at AACR
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

Post Your Comments:
(Date:11/6/2009)..., MURRYSVILLE, Pa., Nov. 6 Phili... for Disease Control and Prevention (CDC) to raise...-- chronic sleep insufficiency. The CDC,s release ...e-by-state differences in sleeplessness is a miles...lem. ,, As a long-time educator, industry lead...
(Date:11/6/2009)..., HOUSTON, Nov. 6 Cybe... the company will report financial results for the...al year ending April 30, 2010 on Wednesday, Novemb...uct a conference call to discuss those results on ... Fiscal Year 2010 Second Quarter Results Conferen...
(Date:11/6/2009)..., PARIS, November 6 , ...gent Linezolid for the,Treatment of Multi-Resistan... Novexel, a speciality pharmaceutical company fo...tibiotics designed to overcome the significant glo...ay that its most advanced oral,antibacterial NXL10...
Breaking Medicine Technology:Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Gene Data Tool Advances Prospects for Personalized Medicine 59221 1Gene Data Tool Advances Prospects for Personalized Medicine 59221 2Gene Data Tool Advances Prospects for Personalized Medicine 59221 3Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 1Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 2Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 3BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 1BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 2BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 3BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 4
...oPharmaceutics, Inc.,an emerging biopharmaceutical... demonstrating the utility of their lead drug cand...blood disorder paroxysmal nocturnal,hemoglobinuria...the XXII,International Complement Workshop in Base...tment currently available for PNH patients is an a...
...ork with Protein Therapeutics that Modul...BRIDGE, Mass., July 23 Taligen Therapeutics Inc.,...h plan with the,appointment of Abbie Celniker, Ph....nt of its headquarters in Cambridge, Mass. Dr. Cel...of the company who remains president., Under Dr. ...
Other Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3
(Date:11/8/2009)...rk of Hispanic health advocates committed to achie...WASHINGTON, Nov. 7 "Ton... have heard the voice of America,s families by pas...ow the Senate must deliver, without delay, on the .... Jane L. Delgado, President and CEO of the Nation...
(Date:11/8/2009)...e of H.R. 3961 to Secure the Stability of Medicare... Statement Attributable to: J. James Rohack, M.D.,...ogo: http://www.newscom.com/cgi-bin/prnh/2008120...the House health reform bill, which will help impr...and calls for swift passage of H.R. 3961 to secure...
(Date:11/8/2009)... Who Sides With Working Families vs. Insurance Com...USNewswire/ -- On the heels of an historic late ni...d, balanced health care reform bill, the Pennsylva...s U.S. representatives voted on HR 3962, the Affor...slation, which passed Saturday evening by a vote o...
(Date:11/7/2009)...ewswire-USNewswire/ -- Karen Ignagni, President an...released the following statement today on House pa...upport comprehensive health care reform, and we ha...omplete overhaul of how health insurance is provid...rage, elimination of pre-existing condition exclus...
(Date:11/7/2009)...wire-USNewswire/ -- The American Medical Associati... Health at the Family Violence Prevention Fund, wi... its semi-annual policy-making meeting. The Citat... the AMA House of Delegates bestows on a non-physi...-bin/prnh/20081209/AMALOGO ) ,, "Ms. James ha...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Family Violence Prevention Expert 2
...ETON, N.J., May 18 Covance Inc. (NYSE: CVD ) to... Bank 34th Annual Health Care Conference on Tuesda...access a live webcast of the presentation at www...n, New Jersey, is one of the world,s largest and m...
...ein AV300 Helps Healthcare Professionals Locate Ha...Care in Venipuncture, Most Common Invasive Medical... AccuVein LLC today announced the launch of Acc...s and blood draws (venipuncture) can be a source o...
..., , NCCN recently updated the NCCN Guidelines for...ew updates include the recommendation to use bevac...a multiforme in CNS cancers, the integration of a ...ow grade gliomas. , , FORT WASHINGTON, Pa., May 1...
...ose who only think they,re fat face higher risk,...y News) -- Overweight teens, or those who believe ...mpt suicide, according to a U.S. study. , Research...en,s belief that he or she might be overweight -- ...
...s enough capacity for typical season; experts less... 18 (HealthDay News) -- The current swine flu outb...g of bringing a new vaccine to market and the logi...l influenza vaccine, experts say. If they wait too...
...ORK, May 18 The 2nd Annual Disability Leadersh...ith Disabilities, a unique gathering to promote a...es and public officials, disability rights advocat... NY. , , Featured speakers and their topics incl...
Other Medicine News:Health News:Video: AccuVein Launches First Portable, Non-Contact Vein Illumination Device 2Health News:Video: AccuVein Launches First Portable, Non-Contact Vein Illumination Device 3Health News:NCCN Updates Guidelines for Central Nervous System (CNS) Cancers 2Health News:NCCN Updates Guidelines for Central Nervous System (CNS) Cancers 3Health News:Worries About Weight Are Tied to Teen Suicide Tries 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:United Spinal Association's 2nd Annual Disability Leadership & Policy Summit: Health Issues and People with Disabilities 2
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
Medicine Products: